Italia markets closed

Dow Jones
39.739,27
-133,72(-0,34%)
Nasdaq
16.787,65
-44,97(-0,27%)
Nikkei 225
38.617,10
-329,83(-0,85%)
EUR/USD
1,0840
-0,0019(-0,17%)
Bitcoin EUR
64.444,89
+37,69(+0,06%)
CMC Crypto 200
1.515,58
-10,84(-0,71%)

NVCR Dec 2025 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

6,70

0,00

(0,00%)

In data: 10:52AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in